EcoDrugPlus

Acetylcholinesterase (Cartwright Blood Group)

Ensembl ID : ENSPNAG00000018355
Gene Symbol: ACHE
3 Cross references
233 Possible Orthologues:

Activin A Receptor Type 2b

Ensembl ID : ENSPNAG00000024111
Gene Symbol: ACVR2B
3 Cross references
195 Possible Orthologues:

Activin Receptor Type-2b

Ensembl ID : ENSPNAG00000027259
Gene Symbol: LOC108436077
3 Cross references
193 Possible Orthologues:

Adenosine A1 Receptor

Ensembl ID : ENSPNAG00000011747
Gene Symbol: ADORA1
3 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor

Ensembl ID : ENSPNAG00000008697
Gene Symbol: ADORA2A
4 Cross references
198 Possible Orthologues:

Adenosine A2a Receptor A

Ensembl ID : ENSPNAG00000010483
Gene Symbol: ADORA2AA
1 Cross references
189 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSPNAG00000002423
Gene Symbol: ADORA3
3 Cross references
114 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSPNAG00000029323
Gene Symbol: ADORA3
1 Cross references
114 Possible Orthologues:

Adenosine A3 Receptor

Ensembl ID : ENSPNAG00000026670
Gene Symbol: ADORA3
3 Cross references
119 Possible Orthologues:

Adenosine Deaminase

Ensembl ID : ENSPNAG00000019259
Gene Symbol: ADA
3 Cross references
216 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSPNAG00000010336
Gene Symbol: LOC108414989
3 Cross references
152 Possible Orthologues:

Adenosine Receptor A1-Like

Ensembl ID : ENSPNAG00000002422
Gene Symbol: LOC108433661
2 Cross references
114 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).